DBV Biotech (DBV Technologies) is a French biotech company specializing in epicutaneous immunotherapy for food allergies through its Viaskin® platform, notably the Viaskin Peanut (peanut) and Viaskin Milk patches, with ongoing clinical programs (Viaskin Egg in preclinical). The EPIT technology delivers micro-doses of allergens through the skin to retrain the immune system. The company is led by CEO Daniel Tassé and among its founders are Pierre-Henri Benhamou, Bertrand, and Christophe Dupont. Its flagship patch, Viaskin Peanut, is progressing towards a Biologics License Application (BLA) with the FDA following promising Phase 3 results.
Create a free account to unlock the AI analysis, news, momentum and full price history for DBV TECHNOLOGIES — and every other stock.
Create a free account